Modality
Bispecific Ab
MOA
BCMA ADC
Target
Tau
Pathway
JAK/STAT
Pompe
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
Jul 2022
→ Aug 2031
Phase 1Current
NCT07484250
1,197 pts·Pompe
2022-07→2031-08·Active
NCT04939996
1,583 pts·Pompe
2023-06→2026-07·Not yet recruiting
2,780 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-073mo awayPh2 Data· Pompe
2031-08-245.4y awayPh2 Data· Pompe
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Active
P1/2
Not yet…
Catalysts
Ph2 Data
2026-07-07 · 3mo away
Pompe
Ph2 Data
2031-08-24 · 5.4y away
Pompe
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07484250 | Phase 1/2 | Pompe | Active | 1197 | OS |
| NCT04939996 | Phase 1/2 | Pompe | Not yet recr... | 1583 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR | |
| TER-5062 | Terns | Phase 2/3 | Tau |